This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug

25

Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sep

10

Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

Oct

08

Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Menu

Hansoh Pharma's EGFR-Mutated Lung Cancer Drug Gains Market Authorization in China

To read the full story....

Breaking News

T-Cure Bioscience, NHLBI Collaborate to Advance Targeted T-Cell Receptor Therapy

BostonGene Partners With Dana-Farber's Weinstock Lab on T-Cell Lymphoma Biomarker Research

Natera's Signatera ctDNA Test Shows Immunotherapy Response Prediction Capability in Advanced Cancer

Roche's Rozlytrek Garners Conditional Authorization in Europe for Cancers With NTRK, ROS1 Fusions

FDA Approves Genentech's Tecentriq, Cotellic, Zelboraf for BRAF V600-Mutated Melanoma

European Commission Approves Novartis' Piqray, Fulvestrant for PIK3CA-Mutated Breast Cancer

Featured White Papers

Utility of Novel RNA-Based Tools in Oncology Drug Development

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

What's Popular?

Natera's Signatera ctDNA Test Shows Immunotherapy Response Prediction Capability in Advanced Cancer

Puma's Nerlynx Offers Targeted Treatment Opportunity for HER2-Mutant Cervical Cancer in Basket Trial

BostonGene Partners With Dana-Farber's Weinstock Lab on T-Cell Lymphoma Biomarker Research

Roche's Rozlytrek Garners Conditional Authorization in Europe for Cancers With NTRK, ROS1 Fusions

Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications

Sponsorships